Vioxx Route To Re-Approval Outlined By FDA As Merck Mulls Options
Executive Summary
Conflicting opinions from FDA advisory committee members on the safety of Vioxx necessitates additional committee consideration prior to re-approval of the COX-2 inhibitor, an FDA memo states
You may also be interested in...
GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses
GlaxoSmithKline is pushing back the anticipated NDA filing date for its Phase II COX-2 inhibitor to complete a cardiovascular safety study at the request of FDA, CEO J.P. Garnier said during an earnings call April 28
GSK’s COX-2 Plans: Complete Cardio Safety Study, Test Efficacy Of Low Doses
GlaxoSmithKline is pushing back the anticipated NDA filing date for its Phase II COX-2 inhibitor to complete a cardiovascular safety study at the request of FDA, CEO J.P. Garnier said during an earnings call April 28
COX-2 Review Highlights “Conundrum” Of FDA Drug Safety Regulation
FDA's summary of the COX-2 inhibitor safety review underscores the "conundrum" posed by drug safety regulation